Zerbaxa

Chemical Nameceftolozane/tazobactam
Dosage FormInjection (intravenous; ceftolozane/tazobactam: 1 g/0.5 g)
Drug ClassInhibitors
SystemUrinary, Respiratory
CompanyMerck & Co.
Approval Year2014

Indication

  • Indicated in combination with metronidazole in patients 18 years or older for the treatment of complicated intra-abdominal infections (cIAI) caused by designated susceptible microorganisms.
  • Indicated in patients 18 years or older for the treatment of complicated urinary tract infections (cUTI) (including pyelonephritis) caused by designated susceptible microorganisms.
  • Indicated in patients 18 years or older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by designated susceptible microorganisms.
Last updated on 7/13/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Zerbaxa (ceftolozane/tazobactam) Prescribing Information.2022Merck Sharp & Dohme LLC, Rahway, NJ
Document TitleYearSource
Assessment report: Zerbaxa. 2019EMA